Abeona Therapeutics Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 9, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Share count: 57,146,840 shares of common stock were outstanding as of November 5, 2026, according to the filing.
- Exchange listing: Abeona Therapeutics trades on the Nasdaq Capital Market under the symbol ABEO with common stock carrying a $0.01 par value.
- Commercialized product: The filing identifies ZEVASKYN as the company's approved product, with commercialization and manufacturing activities described as ongoing focal points.
- Pipeline asset: ABO-801 is cited as an acquired pipeline candidate, with the company noting its ability to consummate a private placement transaction announced on November 9, 2026.
- Filer classification: Abeona Therapeutics is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
- Ophthalmology programs: The filing references the deprioritization of the company's AAV-based ophthalmology programs as a subject of forward-looking disclosure.
Abeona Therapeutics Q3 2026: ZEVASKYN Commercialization and Pipeline Updates
Abeona Therapeutics Inc. (NASDAQ:ABEO), a Delaware-incorporated biopharmaceutical company headquartered at 6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025, along with management's discussion and analysis of financial condition and results of operations.
According to the filing, ZEVASKYN is the company's commercially approved product. The registrant described several manufacturing-related considerations tied to ZEVASKYN, including the requirement that qualified treatment centers obtain biopsy samples of sufficient quality to serve as starting material, patient-to-patient variability in cell growth during manufacturing, an 84-hour shelf-life constraint before surgical application can be performed, and the FDA's existing product release specifications implemented based on a limited clinical dataset. The company also disclosed that its ability to generate revenue depends on activating additional qualified treatment centers and those centers enrolling and treating patients.
The filing also references ABO-801, an asset the company disclosed it acquired, and ABO-701, described as a pipeline candidate for which the company is working toward submitting an investigational new drug application. Additionally, the registrant noted a licensing agreement with Ultragenyx related to FAYUVI, under which Abeona may receive milestone, royalty, or other payments depending on commercial demand. The company further disclosed that a private placement transaction was announced on November 9, 2026, the same date as this filing, though the closing of that transaction remained subject to conditions described as forward-looking by the registrant. All forward-looking statements in the filing are the company's own and are subject to its cautionary language regarding risks and uncertainties.
What Was Disclosed
Abeona Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 57,146,840 shares outstanding, its ZEVASKYN commercialization status, pipeline candidates ABO-801 and ABO-701, a licensing arrangement with Ultragenyx, and a November 9, 2026 private placement announcement.




Please wait processing your request...